|
Accueil > Actualité
GSK: positive results from Phase IIb study in HIV
(CercleFinance.com) - GSK reports positive results from a Phase IIb study conducted by its HIV specialist ViiV Healthcare.
The study showed that N6LS (VH3810109 or VH109), administered every four months in combination with monthly long-acting cabotegravir (CAB LA), maintained suppressed viral load in treatment-stabilized adults living with HIV. N6LS was well tolerated by participants, says the company. These results were presented today at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco, USA. Copyright (c) 2025 CercleFinance.com. All rights reserved. |
28/03/2025 17:20
BMWmise en service d'un nouvel atelier à Ratisbonne 28/03/2025 16:56 Intelle second volet de l'opération SK hynix est bouclé 28/03/2025 16:34 Equinorsigne un contrat de 330 M$ avec Island Drilling 28/03/2025 16:24 Memscaple titre surnage grâce à son carnet de commandes 28/03/2025 16:10 Hexaomchute de 58% du résultat net annuel 28/03/2025 15:55 Nanobiotixdes données favorables dans le CPNPC Tous les articles sociétés |
